Abstract. Serine/threonine kinase 39 (STK39) is associated with hypertension, autism, Parkinson's disease and various types of cancer in recent years. This study investigated STK39 expression and possible roles in osteosarcoma using qPCR and western blot analysis. Compared to normal bone tissues, the mRNA and protein expression of STK39 was found to be upregulated in osteosarcoma. Using small interfering RNA transfection, STK39 was knocked down into two cell lines of osteosarcoma, U2OS and MG63, and the effects exerted on cell functioning were examined. The results showed that STK39 downregulation inhibited osteosarcoma cell proliferation and invasion. Moreover, STK39 knockdown in osteosarcoma cells significantly affected the expression of proteins connected to cell proliferation (proliferating cell nuclear antigen and p21) and invasion [Twist1, matrix metalloproteinase (MMP)2 and MMP9]. Phosphorylation of Smad2/3 was reduced by STK39 knockdown. In conclusion, our data provide evidence that STK39 was overexpressed in osteosarcoma. STK39 may serve as an oncogene by adjusting the proliferation and invasion of osteosarcoma cells.

Introduction

Osteosarcoma is a kind of primary bone tumor most commonly seen in juveniles (1). The five-year survival rate of this disease has risen to 50-60% thanks to aggressive progress in diagnostic and treating technologies (2,3). However, the same outcomes are not applicable for patients with metastasis or recrudescent disease (4).

Therefore, it is crucial to optimize therapeutic options and improve the prognosis by exploring the mechanism of molecule that underlies the development and progression of osteosarcoma.
CTTAATGTCACGCACGAT-3'. The expression of STK39 mRNA was calculated using the 2 \(^{-\Delta\Delta Cq} \) method.

**Western blot analysis.** Protein lysate was prepared from tissue samples and cell lines with RIPA lysis buffer supplemented with protease inhibitor cocktail (Sigma, St. Louis, MO, USA). Equal amounts of protein were electrophoresed on an SDS-PAGE gel, and transferred onto a nitrocellulose membrane (Millipore, Bradford, PA, USA). After dilution in 5% skimmed milk, the membrane was incubated with rabbit polyclonal STK39 antibody (dilution, 1:500; cat. no. ab71825); rabbit monoclonal p21 antibody (dilution, 1:500; cat. no. ab109520); rabbit polyclonal Twist1 antibody (dilution, 1:500; cat. no. ab50581); rabbit polyclonal MMP-2 antibody (dilution, 1:500; cat. no. ab37150); rabbit polyclonal MMP-9 antibody (dilution, 1:500; cat. no. ab38898); rabbit polyclonal PCNA antibody (dilution, 1:500; cat. no. ab18197); rabbit polyclonal pSmad2/3 antibody (dilution, 1:500; cat. no. ab36372) and rabbit polyclonal Smad2/3 antibody (dilution, 1:500; cat. no. ab217553) overnight at 4˚C and then incubated with secondary goat anti-rabbit (HRP) IgG antibody (dilution, 1:2,000; cat. no. ab6721). Signals were detected using enhanced chemiluminescence (Bio-Rad, Richmond, CA, USA) and analyzed with ImageJ software (http://rsb.info.nih.gov/ij/; Bethesda, MD, USA) with β-actin as a loading control. All the antibodies were all purchased from Abcam (Cambridge, MA, USA).

**Cell cultivation.** The Cell Bank of Shanghai Biology Institute, Chinese Academy of Science (Shanghai, China) provided the human osteosarcoma cells, MG6 and U2OS, which were grown in Dulbecco's modified Eagle's medium (DMEM) (Life Technologies, Carlsbad, CA, USA) supplemented with 1% penicillin/streptomycin and 10% fetal bovine serum (FBS), (Life Technologies) at a temperature of 37°C and an atmosphere of 5% CO₂.

**Small interfering RNAs (siRNAs).** STK39 siRNA (siSTK39, 5'-CCCACCCCAUGCUAUGAA-3') and control siRNA (siNC, 5'-UUCUCCGAACGUGUCAGU-3') were produced by Genepharm Technologies (Shanghai, China). MG63 and U2OS cells were infected with siSTK39 or siNC using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen). After a 48-h transfection, qPCR and western blot analysis assayed the knockdown efficiency.

**Cell proliferation assay.** During the logarithmic phase, MG63 and U2OS cells were implanted into 96-well plates at a density of 3x10³ cells per well. After adhering to culture plates, the cell lines were transfected with siSTK39 or siNC and incubated for 0, 24, 48 and 72 h. We then incubated the cells using a Cell Counting kit (CCK)-8 reagent (Beyotime Institute of Biotechnology, Shanghai, China) at a temperature of 37°C for another hour. Using a microplate reader (Bio-Rad), we detected optical density (OD) values with wavelength of 450 nm.

**Boyden chamber assay for invading.** Matrigel-coated Boyden chamber (BD Biosciences, Becton Dickinson and Company, CA, USA) were used for the cell invasion assays. Briefly, the cells were transfected with siRNAs in a 60-mm dish as described above. After the serum was starved for 24 h, the cells were harvested and resuspended in serum-free DMEM. Cells (5x10⁴) (in 500 μl medium) and DMEM containing 10% FBS were added to the upper and lower chambers, respectively. After 24 h, the cells on the membrane's upper side were completely transferred. The membranes were fixed with 4% paraformaldehyde and stained with 0.5% crystal violet. The cells were counted using an inverted microscope (Nikon Eclipse E800; Tokyo, Japan).

**Statistical analysis.** GraphPad Prism software version 6.0 (San Diego, CA, USA) was used for the statistical analyses. The Student's t-test determined the statistical significance of STK39 expression between different groups. We performed cell tests in triplicate, which were repeated no less than three times and analyzed using one-way analysis of variance. P<0.05 was considered statistically significant.

**Results**

**STK39 upregulated expression in osteosarcoma.** By applying qPCR, we first examined STK39 mRNA expression in
15 normal bone tissues and 25 osteosarcoma tissues collected from Shanghai First People's Hospital, Baoshan Branch. Compared to the normal bone tissues (Fig. 1A, P<0.0001), the results showed that STK39 expression was obviously upregulated in osteosarcoma tissues. We then performed western blot analysis in four pairs of available samples of tissue. The results indicated that STK39 protein expression was also abundant in osteosarcoma tissues (Fig. 1B, P<0.05).

**RNAi knockdown of STK39.** To examine the role of STK39 in osteosarcoma cells, we knocked down its expression by siRNA transfection in U2OS and MG63 osteosarcoma cells (Fig. 2). siNC had no effect on the expression of STK39 as compared to cells without any treatment. STK39 siRNA (siSTK39) efficiently suppressed the mRNA (Fig. 2A) and protein levels (Fig. 2B) of STK39 in the two osteosarcoma cells as compared to cells transfected with siNC.

**STK39 knockdown inhibits osteosarcoma cell proliferation.** The ability of cell production was evaluated using CCK-8 assay in the two osteosarcoma cells. As shown in Fig. 3, the cells transfected with siNC had a similar proliferation rate with cells without any treatment, while siSTK39 transfection significantly decreased cell proliferation at 48 and 72 h compared with siNC. These data indicated that STK39 may promote osteosarcoma proliferation.

**STK39 knockdown suppresses the invasion of osteosarcoma cells.** The invasion ability was then measured by Matrigel-coated Transwell assay. As shown in Fig. 4, the invaded cell number was decreased by 42.0 and 46.2% in siSTK39-transfected U2OS and MG63 cells, respectively, in contrast to siNC-transfected cells.

**Effects of STK39 knockdown on the expression of relevant proteins.** We detected the protein levels of cell proliferation [proliferating cell nuclear antigen (PCNA) (14) and p21 (15)] and invasion-related proteins in osteosarcoma cells (Fig. 5). The representation of PCNA, Twist1, MMP-2 and MMP-9 was significantly decreased, while p21 representation increased significantly in osteosarcoma cells transfected with siSTK39 compared to those transfected with siNC (16).

**STK39 knockdown represses the phosphorylation of Smad2/3.** Transforming growth factor (TGF)-β signaling has been found to promote osteosarcoma cell proliferation and invasion (17,18). We analyzed the phosphorylation protein levels of Smad2/3, an important downstream of TGFβ, in osteosarcoma cells by
Figure 4. Knockdown of STK39 expression inhibits osteosarcoma cell invasion. (A) U2OS and (B) MG63 cells were transfected with indicated siRNA. Invasion assay was performed using Matrigel-coated Transwell assay. Typical pictures (left) and quantifiable outcomes (right) are shown. **P<0.01, ***P<0.001 vs. siNC. STK39, serine/threonine kinase 39.

Figure 5. Effects of STK39 knockdown on the expression of relevant proteins. (A) U2OS and (B) MG63 cells were transfected with indicated siRNA. After 48 h, western blotting was used to determine protein levels of cell proliferation (PCNA and p21) and invasion-related proteins (Twist1, MMP-2 and MMP-9). Representative blots (left) and quantification results (right) are shown. **P<0.01, ***P<0.001 vs. siNC. STK39, serine/threonine kinase 39; PCNA, proliferating cell nuclear antigen.

Figure 6. Effects of STK39 knockdown on p-Smad2/3 and Smad2/3 protein expression. Western blotting was used to identify protein levels in p-Smad2/3 and Smad2/3 in (A) U2OS and (B) MG63 cells at 6 h after siRNA transfection. Representative blots (left) and quantification results (right) are shown. ***P<0.001 vs. siNC. STK39.
western blot analysis at 6 h after siRNA treatment. As shown in Fig. 6, siSTK39 significantly decreased p-Smad2/3/Smad2/3 relative representation degrees in both U2OS and MG63 cells. These data suggested the involvement of TGF/Smad2/3 in STK39 functions on osteosarcoma cells.

Discussion

Current studies have increasingly focused on the expression of STK39 in osteosarcoma tissues. Suppression of STK39 expression inhibited cell proliferation and invasion of U2OS and MG63 cells. STK39 knockdown had a significant impact on the expression of cell proliferation and proteins related to invasion. Furthermore, STK39 knockdown suppressed the phosphorylation of Smad2/3, downstream of TGF. Thus, the results of the present study suggest that STK39 may serve as an oncogene in the development of osteosarcomas.

Increasing investigations have indicated that STK39 is relevant to human disease, including various types of cancer (11-13). The decreased mRNA level of STK39 is strongly related with the higher incidence of metastases in patients with primary prostate cancers (11). By contrast, the higher protein level of STK39 is positively correlated with more advanced lymph node metastasis and poorer prognosis in patients with large cell carcinoma and tumor non-small cell lung cancer (NSCLC) (14). Knockdown of STK39 in B-cell lymphomas promotes cancer progression by impairing caspase activation (12), while its knockdown in NSCLC cells significantly decreased cell proliferation, migration and invasion (13). Thus, different organ systems and separate cellular conditions in tumors lead to the double role of STK39. To the best of our knowledge, the expression and role of STK39 in osteosarcoma remains to be determined. The present study has compared STK39 expression in osteosarcoma cells, control standard bone cells, and suggests that osteosarcoma tissues lead to the overexpression of STK39. Furthermore, previous findings have shown that, knockdown of STK39 inhibits the proliferation and invasion of osteosarcoma cells. These results are consistent with studies conducted on NSCLC (13). Therefore, STK39 is an oncogene that regulates the development and spread of osteosarcomas.

In addition, we showed that knocking down STK39 expression influenced the expression of cell development and proteins related to invasion. p21 is a universal inhibitor for male hypertension in Han Chinese. Int J Cardiol 154: 122-127, 2012.

References

1. Gill J, Abluwalia MK, Geller D and Gorlick R: New targets and approaches in osteosarcoma. Pharmacol Ther 137: 89-99, 2013.
2. Tan ML, Choong PF and Dass CR: Osteosarcoma: Conventional treatment vs gene therapy. Cancer Biol Ther 8: 106-117, 2009.
3. Bakshisi S and Radhakrishnan V: Prognostic markers in osteosarcoma. Expert Rev Anticancer Ther 10: 271-287, 2010.
4. Guise TA, O’Keefe R, Randall RL and Terek RM: Molecular biology and therapeutics in musculoskeletal oncology. J Bone Joint Surg Am 91: 724-732, 2009.
5. Ramoz N, Cai G, Reichert JG, Silverman JM and Buxbaum JD: An analysis of candidate autism loci on chromosome 2q24-q3: evidence for association to the STK39 gene. Am J Med Genet B Neuropsychiatr Genet 147B: 1152-1158, 2008.
6. Johnston AM, Naselli G, Gonzalez LJ, Martin RM, Harrison LC and DeAizpurua HJ: SPAK, a STE20/SPS1-related kinase that activates the p38 pathway. Oncogene 19: 4290-4297, 2000.
7. Chen LY, Zhao WH, Tian W, Guo J, Jiang F, Jin LJ, Sun YX, Chen KM, An LL, Li GD, et al: STK39 is an independent risk factor for male hypertension in Han Chinese. Int J Cardiovasc Dis 154: 122-127, 2012.
15. Gartel AL and Radhakrishnan SK: Lost in transcription: p21 repression, mechanisms and consequences. Cancer Res 65: 3980-3985, 2005.

16. Yang G, Yuan J and Li K: EMT transcription factors: Implication in osteosarcoma. Med Oncol 30: 697, 2013.

17. Matsuyama S, Iwadate M, Kondo M, Saitoh M, Hanyu A, Shimizu K, Aburatani H, Mishima HK, Imamura T, Miyazono K, et al: SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. Cancer Res 63: 7791-7798, 2003.

18. Li F, Li S and Cheng T: TGF-β1 promotes osteosarcoma cell migration and invasion through the miR-143-versican pathway. Cell Physiol Biochem 34: 2169-2179, 2014.

19. Waga S, Hannon GJ, Beach D and Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578, 1994.

20. Wang W, Luo H and Wang A: Expression of survivin and correlation with PCNA in osteosarcoma. J Surg Oncol 93: 578-584, 2006.

21. Cottam D and Rees R: Regulation of matrix metalloproteinsases - their role in tumor invasion and metastasis (Review). Int J Oncol 2: 861-872, 1993.

22. Yin K, Liao Q, He H and Zhong D: Prognostic value of Twist and E-cadherin in patients with osteosarcoma. Med Oncol 29: 3449-3455, 2012.

23. Massague J: TGF-β signaling in development and disease. FEBS Lett 586: 1833-1833, 2012.